aspirin has been researched along with Obesity in 161 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this secondary analysis of a randomized controlled trial involving patients with minor ischemic stroke or TIA, compared with clopidogrel-ASA, patients with obesity received more clinical benefit from ticagrelor-ASA therapy than those without obesity." | 9.69 | Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack. ( Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X, 2023) |
| "These findings suggest that individuals with twin pregnancies, a history of preeclampsia, or hypertension may not benefit from aspirin to the same extent as those with other complications such as obesity or diabetes." | 9.69 | Persisting risk factors for preeclampsia among high-risk pregnancies already using prophylactic aspirin: a multi-country retrospective investigation. ( Corsi, DJ; Dagvadorj, A; Dingwall-Harvey, ALJ; El-Chaár, D; Gaudet, LM; Guo, Y; McLean, C; Muldoon, KA; Rennicks White, R; Rybak, N; Walker, MC; Wen, SW, 2023) |
| "Late timing of intervention and maternal obesity are potential explanations for the modest effect of aspirin for preeclampsia prevention." | 9.20 | Is low-dose aspirin therapy to prevent preeclampsia more efficacious in non-obese women or when initiated early in pregnancy? ( Abramovici, AR; Biggio, JR; Cantu, JA; Edwards, RK; Jauk, VR; Owen, J; Tita, AT, 2015) |
| "Obesity is associated with substantially increased CRC risk in patients with LS, but this risk is abrogated in those taking aspirin." | 9.20 | Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. ( Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, MG; Eccles, D; Evans, DG; Ho, JW; Hodgson, SV; Lindblom, A; Lubinski, J; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Moeslein, G; Morrison, PJ; Movahedi, M; Murday, V; Olschwang, S; Ramesar, RS; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2015) |
| "The pharmacologic effect of aspirin is suboptimal in 15% of patients with SLE but in none of the control subjects, and the suboptimal response was associated with metabolic syndrome, obesity, and higher CRP concentrations." | 9.19 | Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome. ( Avalos, I; Chung, CP; Kawai, VK; Milne, GL; Oates, JA; Oeser, A; Solus, JF; Stein, CM, 2014) |
| " The aim of this prospective, randomised, study was to compare the PD effects of standard-dose prasugrel [60 mg loading dose (LD)/10 mg daily maintenance dose (MD)] with high-dose clopidogrel (900 mg LD/150 mg daily MD) in non-diabetic obese [body mass index (BMI) ≥30 kg/m²] patients, with coronary artery disease (CAD) on aspirin therapy." | 9.19 | Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014) |
| "These data suggest that glycemic control, obesity, and the dose of aspirin have influence on AR in diabetic subjects." | 9.14 | Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. ( Akin, O; Ata, N; Deveci, OS; Ertugrul, DT; Küçükazman, M; Tutal, E; Ure, OS; Yalçin, AA; Yavuz, B; Yildiz, M; Yilmaz, H, 2010) |
| "Parenteral administration of gold thioglucose to mice produces an area or necrosis in the ventromedial portion of the hypothalamus." | 8.75 | Gold thioglucose obesity syndrome. ( Debons, AF; Fani, K; Jemenez, FA; Krimsky, I; Maayan, ML, 1977) |
| " Aspirin is known as a potent anti-inflammatory drug, but its role in adipogenesis, adipocyte-specific inflammation, and metabolic syndrome is not well characterized." | 8.12 | Aspirin attenuates the expression of adhesion molecules, risk of obesity, and adipose tissue inflammation in high-fat diet-induced obese mice. ( Ahmed, F; Amin, MT; Begum, R; Bhowmik, DR; Hossain, MS; Islam, MA; Roy, S, 2022) |
| "To evaluate how prediagnosis obesity and postdiagnosis aspirin use may be associated with overall survival in patients with late-stage colorectal cancer." | 8.12 | Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. ( Advani, SM; Chang, S; Chavez, JC; Dasari, A; Davis, JS; Fogelman, D; Henderson, H; Johnson, B; Kee, B; Kok, M; Kopetz, S; Lee, HY; Maru, D; Menter, DG; Meric-Bernstam, F; Morris, V; Overman, MJ; Parseghian, C; Raghav, KP; San Miguel, Y; Shaw, KR; Shen, JP; Shureiqi, I; Vilar, E; Wolff, RA, 2022) |
| "Despite the overall association of aspirin on reduced hepatocellular carcinoma (HCC) risk, there have been few studies on its benefit according to specific clinical conditions among hepatitis B virus (HBV)-infected patients." | 8.12 | Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study. ( Ahn, SH; Kim, BK; Yoon, JH; Yun, B, 2022) |
| "Whether aspirin or other nonsteroidal anti-inflammation drug (NSAID) use is associated with mortality following breast cancer remains unclear." | 7.88 | Pre-diagnostic aspirin use and mortality after breast cancer. ( Bradshaw, PT; Gammon, MD; McClain, KM; Neugut, AI; Parada, H; Teitelbaum, SL; Terry, MB; Wang, T, 2018) |
| "We compared outpatients with difficult-to-treat asthma (DTA; n = 486) in a tertiary hospital for allergic diseases in central Japan with those with controlled severe asthma (n = 621) with respect to clinical factors including body mass index (BMI) and aspirin intolerance using multivariate logistic regression analysis stratified by gender and atopic phenotype." | 7.78 | Obesity and aspirin intolerance are risk factors for difficult-to-treat asthma in Japanese non-atopic women. ( Akiyama, K; Fukutomi, Y; Hasegawa, M; Higashi, N; Mori, A; Nakamura, H; Ono, E; Oshikata, C; Sekiya, K; Taniguchi, M; Tanimoto, H; Tsuburai, T, 2012) |
| "High-dose aspirin treatment improves fasting and postprandial hyperglycaemia in patients with type 2 diabetes, as well as in animal models of insulin resistance associated with obesity and sepsis." | 7.75 | Aspirin attenuates insulin resistance in muscle of diet-induced obese rats by inhibiting inducible nitric oxide synthase production and S-nitrosylation of IRbeta/IRS-1 and Akt. ( Carvalheira, JB; Carvalho-Filho, MA; Cintra, DE; Curi, R; Pauli, RJ; Ropelle, ER; Saad, MJ; Silveira, LR; Tsukumo, DM; Velloso, LA, 2009) |
| "Aspirin provocation tests were performed in 667 asthmatic patients and changes in FEV(1) were used to categorize patients as ATA or AIA." | 7.74 | Obesity in aspirin-tolerant and aspirin-intolerant asthmatics. ( Jang, AS; Kim, DJ; Kim, YH; Park, CS; Park, HS; Park, JS; Park, SW; Seo, KH; Uh, ST, 2008) |
| " The aims of the present study were: to verify the incidence of Normal Weight Obese (NWO) syndrome; to evaluate by PINI the effect of 8 weeks acetyl salicylic (100 mg/die) and atorvastatin (10 mg/die) combined treatment on chronic inflammation in 52 selected HD patients." | 7.74 | Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome. ( De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C, 2008) |
| " In contrast, ephedrine increased energy expenditure by 9% and reduced body weight and body fat by 18% and 50%, respectively: obesity, however, was reduced but not reversed." | 7.67 | Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity. ( Dulloo, AG; Miller, DS, 1987) |
| "To investigate whether prostaglandins (PGs) play a role in the regulation of insulin secretion during starvation, we have studied the effects of two inhibitors of PG synthesis, indomethacin (INDO) and acetylsalicylic acid (ASA), on plasma insulin during a 72-h fast." | 7.66 | Indomethacin and aspirin prevent the starvation-induced fall in plasma insulin. ( Brodows, RG; Lilavivathana, U, 1980) |
| "Aspirin is a cornerstone antiplatelet drug that has substantial interpatient variability in pharmacodynamic response and a number of reports have demonstrated that obesity is a risk factor for a reduced aspirin pharmacodynamic response." | 6.58 | Obesity and Altered Aspirin Pharmacology. ( Norgard, NB, 2018) |
| "These findings suggest that individuals with twin pregnancies, a history of preeclampsia, or hypertension may not benefit from aspirin to the same extent as those with other complications such as obesity or diabetes." | 5.69 | Persisting risk factors for preeclampsia among high-risk pregnancies already using prophylactic aspirin: a multi-country retrospective investigation. ( Corsi, DJ; Dagvadorj, A; Dingwall-Harvey, ALJ; El-Chaár, D; Gaudet, LM; Guo, Y; McLean, C; Muldoon, KA; Rennicks White, R; Rybak, N; Walker, MC; Wen, SW, 2023) |
| "In this secondary analysis of a randomized controlled trial involving patients with minor ischemic stroke or TIA, compared with clopidogrel-ASA, patients with obesity received more clinical benefit from ticagrelor-ASA therapy than those without obesity." | 5.69 | Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack. ( Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X, 2023) |
| "Class 1 obesity is associated with enhanced platelet activation in response to AA in patients on dual antiplatelet therapy." | 5.62 | Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity. ( Eichelberger, B; Gremmel, T; Kopp, CW; Lee, S; Panzer, S, 2021) |
| "Aspirin treatment modified metabolites involved in suppressing lipogenesis, oxidative stress, and neoplastic formation." | 5.56 | Aspirin Modifies Inflammatory Mediators and Metabolomic Profiles and Contributes to the Suppression of Obesity-Associated Breast Cancer Cell Growth. ( Chiu, HH; Hsieh, CC; Kuo, CH; Wang, CH, 2020) |
| "Aspirin treatment reduced body weight gain, reversed glucose intolerance, and depressed hepatic lipid accumulation in female, but not in male mice." | 5.51 | Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. ( Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019) |
| "Obesity is a cluster of medical conditions affecting several pathophysiological processes, including platelet (PLT) function." | 5.42 | Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. ( Gąsior, Z; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia-Stec, K, 2015) |
| " During long-term therapy, salicylate dosage for obese individuals should not be adjusted upward in proportion to total weight." | 5.27 | Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. ( Abernethy, DR; Boxenbaum, HG; Greenblatt, DJ; Harmatz, JS; Matlis, R; Ochs, HR; Shader, RI, 1986) |
| "Late timing of intervention and maternal obesity are potential explanations for the modest effect of aspirin for preeclampsia prevention." | 5.20 | Is low-dose aspirin therapy to prevent preeclampsia more efficacious in non-obese women or when initiated early in pregnancy? ( Abramovici, AR; Biggio, JR; Cantu, JA; Edwards, RK; Jauk, VR; Owen, J; Tita, AT, 2015) |
| "Obesity is associated with substantially increased CRC risk in patients with LS, but this risk is abrogated in those taking aspirin." | 5.20 | Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. ( Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, MG; Eccles, D; Evans, DG; Ho, JW; Hodgson, SV; Lindblom, A; Lubinski, J; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Moeslein, G; Morrison, PJ; Movahedi, M; Murday, V; Olschwang, S; Ramesar, RS; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2015) |
| "The pharmacologic effect of aspirin is suboptimal in 15% of patients with SLE but in none of the control subjects, and the suboptimal response was associated with metabolic syndrome, obesity, and higher CRP concentrations." | 5.19 | Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome. ( Avalos, I; Chung, CP; Kawai, VK; Milne, GL; Oates, JA; Oeser, A; Solus, JF; Stein, CM, 2014) |
| " The aim of this prospective, randomised, study was to compare the PD effects of standard-dose prasugrel [60 mg loading dose (LD)/10 mg daily maintenance dose (MD)] with high-dose clopidogrel (900 mg LD/150 mg daily MD) in non-diabetic obese [body mass index (BMI) ≥30 kg/m²] patients, with coronary artery disease (CAD) on aspirin therapy." | 5.19 | Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014) |
| "These data suggest that glycemic control, obesity, and the dose of aspirin have influence on AR in diabetic subjects." | 5.14 | Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. ( Akin, O; Ata, N; Deveci, OS; Ertugrul, DT; Küçükazman, M; Tutal, E; Ure, OS; Yalçin, AA; Yavuz, B; Yildiz, M; Yilmaz, H, 2010) |
| "To examine the roots of asthma across different ages, including atopy, the role of the microbiome and viral infections, and comorbidities and confounders, such as obesity, aspirin-exacerbated respiratory disease, neutrophilic asthma, cigarette smoking, and the possibility of an asthma-chronic obstructive pulmonary disease overlap syndrome." | 4.98 | Heterogeneity and the origins of asthma. ( Grayson, MH; Scherzer, R, 2018) |
| " Increased leptin, dysregulation of adipocyte proteins, increased insulin resistance and C-reactive protein may be factors involved in the increased incidence of cardiovascular morbidity and mortality directly related to obesity." | 4.83 | Stroke prevention in diabetes and obesity. ( Govindarajan, G; Kurukulasuriya, LR; Sowers, J, 2006) |
| "Parenteral administration of gold thioglucose to mice produces an area or necrosis in the ventromedial portion of the hypothalamus." | 4.75 | Gold thioglucose obesity syndrome. ( Debons, AF; Fani, K; Jemenez, FA; Krimsky, I; Maayan, ML, 1977) |
| "Despite the overall association of aspirin on reduced hepatocellular carcinoma (HCC) risk, there have been few studies on its benefit according to specific clinical conditions among hepatitis B virus (HBV)-infected patients." | 4.12 | Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study. ( Ahn, SH; Kim, BK; Yoon, JH; Yun, B, 2022) |
| "The risk factors for SIMBs include aspirin as well as smoking and obesity, and the severity and distributive features of SIMBs differ between aspirin users and non-aspirin users." | 4.12 | Risk factors for small-intestinal mucosal breaks beyond aspirin. ( Chen, X; Liu, J; Sun, X; Wang, F; Wang, M; Wang, Z; Wu, L; Zeng, Q, 2022) |
| " Aspirin is known as a potent anti-inflammatory drug, but its role in adipogenesis, adipocyte-specific inflammation, and metabolic syndrome is not well characterized." | 4.12 | Aspirin attenuates the expression of adhesion molecules, risk of obesity, and adipose tissue inflammation in high-fat diet-induced obese mice. ( Ahmed, F; Amin, MT; Begum, R; Bhowmik, DR; Hossain, MS; Islam, MA; Roy, S, 2022) |
| "To evaluate how prediagnosis obesity and postdiagnosis aspirin use may be associated with overall survival in patients with late-stage colorectal cancer." | 4.12 | Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. ( Advani, SM; Chang, S; Chavez, JC; Dasari, A; Davis, JS; Fogelman, D; Henderson, H; Johnson, B; Kee, B; Kok, M; Kopetz, S; Lee, HY; Maru, D; Menter, DG; Meric-Bernstam, F; Morris, V; Overman, MJ; Parseghian, C; Raghav, KP; San Miguel, Y; Shaw, KR; Shen, JP; Shureiqi, I; Vilar, E; Wolff, RA, 2022) |
| "To investigate the association of aspirin use with risk of all-cause, any cancer, gastrointestinal (GI) cancer, and colorectal cancer (CRC) mortality among older adults and to perform an exploratory analysis of the association of aspirin use with mortality stratified by BMI." | 3.91 | Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Cao, Y; Chan, AT; Loomans-Kropp, HA; Pinsky, P; Umar, A, 2019) |
| "Whether aspirin or other nonsteroidal anti-inflammation drug (NSAID) use is associated with mortality following breast cancer remains unclear." | 3.88 | Pre-diagnostic aspirin use and mortality after breast cancer. ( Bradshaw, PT; Gammon, MD; McClain, KM; Neugut, AI; Parada, H; Teitelbaum, SL; Terry, MB; Wang, T, 2018) |
| " In addition, patients in the 6 am to 2 pm subgroup were more likely older, white race, and male, with higher rates of home aspirin use and lower rates of obesity." | 3.79 | Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. ( Antman, EM; Cannon, CP; Foody, JM; Giugliano, RP; Li, S; Mogabgab, O; Sabatine, MS; Wang, TY; Wiviott, SD, 2013) |
| "High on-aspirin RPR after OPCAB is associated with genetic polymorphism TBXA2R-924TT and obesity." | 3.79 | Polymorphisms and high on-aspirin platelet reactivity after off-pump coronary artery bypass grafting. ( Gao, F; Men, J; Modi, P; Wang, Z; Wei, M; Yang, J, 2013) |
| " This adherence was concerned particularly with co-medication in patients diagnosed with hypertension, aspirin prescription in elderly patients and the achievement of target lipid levels following the prescription of statins." | 3.79 | Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study. ( Hintersteiner, J; Johnson, J; Kamyar, MR; Kautzky, A; Kautzky-Willer, A; Lemmens-Gruber, R; Saukel, J; Stich, K, 2013) |
| "We compared outpatients with difficult-to-treat asthma (DTA; n = 486) in a tertiary hospital for allergic diseases in central Japan with those with controlled severe asthma (n = 621) with respect to clinical factors including body mass index (BMI) and aspirin intolerance using multivariate logistic regression analysis stratified by gender and atopic phenotype." | 3.78 | Obesity and aspirin intolerance are risk factors for difficult-to-treat asthma in Japanese non-atopic women. ( Akiyama, K; Fukutomi, Y; Hasegawa, M; Higashi, N; Mori, A; Nakamura, H; Ono, E; Oshikata, C; Sekiya, K; Taniguchi, M; Tanimoto, H; Tsuburai, T, 2012) |
| " Old age, bilateral diverticulosis, presence of atherosclerosis related diseases (hypertension, diabetes mellitus, ischemic heart disease, obesity), use of aspirin, NSAIDs and calcium channel blocker, increased the risk of bleeding." | 3.78 | [The risk factors for colonic diverticular bleeding]. ( Hwang, JH; Jeong, SH; Jo, HJ; Jung, HC; Kim, HY; Kim, JW; Kim, N; Lee, DH; Lee, SH; Park, H; Park, YS; Seo, PJ; Shin, CM; Song, IS; Suh, S, 2012) |
| "Pre-hospitalization medication such as aspirin and nitrates has been shown to affect the mode of presentation in acute coronary syndrome (ACS)." | 3.77 | Differences in the mode of presentation for acute coronary syndrome by pre-hospitalization medication, in relation to coronary risk factors, East-Osaka acute coronary syndrome (EACS) registry. ( Hoshida, S; Iwasaka, J; Iwasaka, T; Kijima, Y; Lim, YJ; Yuasa, F, 2011) |
| "The USPSTF recommends aspirin for the prevention of stroke and heart attack for those at risk, and screening for major depression and childhood obesity." | 3.76 | USPSTF recommendations you may have missed amid the breast cancer controversy. ( Campos-Outcalt, D, 2010) |
| "High-dose aspirin treatment improves fasting and postprandial hyperglycaemia in patients with type 2 diabetes, as well as in animal models of insulin resistance associated with obesity and sepsis." | 3.75 | Aspirin attenuates insulin resistance in muscle of diet-induced obese rats by inhibiting inducible nitric oxide synthase production and S-nitrosylation of IRbeta/IRS-1 and Akt. ( Carvalheira, JB; Carvalho-Filho, MA; Cintra, DE; Curi, R; Pauli, RJ; Ropelle, ER; Saad, MJ; Silveira, LR; Tsukumo, DM; Velloso, LA, 2009) |
| " Hospital charts review revealed key information for clinical variables, smoking, obesity and use of aspirin at admission." | 3.74 | Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. ( Aguado, J; Castellsague, J; Perez-Gutthann, S; Stang, MR; Tomas, L; Varas-Lorenzo, C, 2008) |
| "Aspirin provocation tests were performed in 667 asthmatic patients and changes in FEV(1) were used to categorize patients as ATA or AIA." | 3.74 | Obesity in aspirin-tolerant and aspirin-intolerant asthmatics. ( Jang, AS; Kim, DJ; Kim, YH; Park, CS; Park, HS; Park, JS; Park, SW; Seo, KH; Uh, ST, 2008) |
| "05) of stroke with hypertension and diabetes mellitus; of myocardial infarction with hypertension, hypercholesterolemia, obesity, and smoking; and of peptic ulcer disease with aspirin, NSAIDs, and potassium." | 3.74 | Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. ( Bilker, WB; Lewis, JD; Schinnar, R; Strom, BL; Wang, X, 2007) |
| " The aims of the present study were: to verify the incidence of Normal Weight Obese (NWO) syndrome; to evaluate by PINI the effect of 8 weeks acetyl salicylic (100 mg/die) and atorvastatin (10 mg/die) combined treatment on chronic inflammation in 52 selected HD patients." | 3.74 | Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome. ( De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C, 2008) |
| "Our results conclude that 10% decrease in body mass index (BMI) among overweight patients, smoking cessation, initiation to undertake a preventive treatment with low-dose aspirin, initiation to undertake or intensify blood pressure control, initiation to undertake or intensify lipidic control, and shift to biguanides among overweight patients are factors associated with significant benefits (avoided costs) which compensate for the increase in treatment costs." | 3.73 | [Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France]. ( Crainich, D; Lebrun, T; Marissal, JP; Sailly, JC, 2005) |
| " The case was complicated due to a history of aspirin usage, marked obesity, and thrombocytopenia." | 3.67 | Femoral artery laceration complicating an intertrochanteric hip fracture: a multi-disciplinary therapeutic problem. ( Chmell, S; Haid, S; Milewski, S; Moss, GD; Pillars, JR, 1985) |
| "To investigate whether prostaglandins (PGs) play a role in the regulation of insulin secretion during starvation, we have studied the effects of two inhibitors of PG synthesis, indomethacin (INDO) and acetylsalicylic acid (ASA), on plasma insulin during a 72-h fast." | 3.66 | Indomethacin and aspirin prevent the starvation-induced fall in plasma insulin. ( Brodows, RG; Lilavivathana, U, 1980) |
| " Guidelines are also inconsistent in the recommendation of routine ASA use for primary prevention of CVD, but advocate dosing as a "one-size-fits-all" approach." | 3.30 | Prospective, randomized, controlled, trial to assess ASA DOSing by body mass index in HEalthy volunteers (DOSE study). ( Hutchinson, D; Kim, K; Kirkham, A; Kroencke, R; Munger, M; Nay, I; Rondina, M; Tolley, ND; Trujillo, T, 2023) |
| " Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization, and bleeding events were analyzed after 1-year follow-up." | 2.78 | Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. ( Gao, W; Ge, H; Guo, Y; Zhang, Q; Zhou, Z, 2013) |
| " (2) Clopidogrel may be under dosed in obese patients." | 2.75 | Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. ( Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C, 2010) |
| "Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed." | 2.69 | Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. ( Alberts, MJ; Berdan, LG; Califf, RM; Deckers, J; Graffagnino, C; Granger, CB; Harrington, RA; Laskowitz, DT; Lincoff, AM; MacAulay, CM; Mahaffey, KW; Miller, JM; Simoons, ML; Sloan, MA; Topol, EJ, 1999) |
| "With aspirin, there was no change in deoxycholate but a decrease in arachidonate and no change in glycoprotein." | 2.67 | Roles of deoxycholate and arachidonate in pathogenesis of cholesterol gallstones in obese patients during rapid loss of weight. ( Bonorris, GG; Marks, JW; Schoenfield, LJ, 1991) |
| "Preventing prostate cancer via dietary supplements should encourage a "first do no harm" or less-is-more approach until future evidence can reverse the concerning trend that more supplementation has resulted in either no impact or an increased risk of prostate cancer." | 2.66 | Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III. ( Moyad, MA, 2020) |
| "Aspirin use was associated with a 29% lower colorectal cancer risk among never-smokers [odds ratios (OR) = 0." | 2.58 | Influence of Smoking, Body Mass Index, and Other Factors on the Preventive Effect of Nonsteroidal Anti-Inflammatory Drugs on Colorectal Cancer Risk. ( Brenner, H; Caan, B; Chan, AT; Chang-Claude, J; Gallinger, S; Hoffmeister, M; Hsu, L; Lampe, JW; Le Marchand, L; Newcomb, PA; Peters, U; Potter, JD; Schoen, RE; Slattery, ML; Wang, X; White, E; Zubair, N, 2018) |
| "Preventing prostate cancer via dietary supplements should encourage a "first do no harm", or less is more approach until future evidence can reverse the concerning trend that more supplementation has resulted in either no impact or an increased risk of prostate cancer." | 2.58 | Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part I. ( Moyad, MA, 2018) |
| "Obesity is a substantial cardiovascular risk factor, and recently, large trials of lifestyle and surgical (e." | 2.50 | Type 2 diabetes and cardiovascular disease: what next? ( Golden, SH; Joseph, JJ, 2014) |
| " There was a significant inverse dose-response (p-trend <0." | 2.49 | Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. ( Nagle, CM; Neill, AS; Obermair, A; Protani, MM; Spurdle, AB; Webb, PM, 2013) |
| "Obesity is associated with increased cardiovascular disease." | 2.48 | Platelet activation in obesity and metabolic syndrome. ( Davì, G; Guagnano, MT; Liani, R; Santilli, F; Vazzana, N, 2012) |
| "Psoriasis is highly prevalent and is associated with skin-associated complaints as well as arthritis, depression and a lower quality of life." | 2.45 | Psoriasis: an opportunity to identify cardiovascular risk. ( Federman, DG; Gunderson, CG; Kirsner, RS; Prodanovich, S; Shelling, M, 2009) |
| "Women with a history of previous preeclampsia are at increased risk of preeclampsia and other adverse pregnancy outcomes in subsequent pregnancies." | 2.44 | Prediction and prevention of recurrent preeclampsia. ( Barton, JR; Sibai, BM, 2008) |
| "The Metabolic syndrome is a widely prevalent and multi-factorial disorder." | 2.43 | Metabolic syndrome. ( Agarwal, PK; Gogia, A, 2006) |
| "The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension." | 2.43 | Dyslipidaemia, hypercoagulability and the metabolic syndrome. ( Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP, 2006) |
| "Therefore, prevention and treatment of diabetic nephropathy has become a prominent goal in the treatment of patients with diabetes mellitus." | 2.42 | Prevention and treatment of diabetic nephropathy in older patients. ( Jungmann, E, 2003) |
| "In the United States, pancreatic cancer is the 4(th) leading cause of cancer death, and in Europe it is the 6th." | 2.42 | Epidemiology of pancreatic cancer. ( Michaud, DS, 2004) |
| "Coronary heart disease is the leading cause of death in women older than 50." | 2.42 | Modifiable risk factors for the primary prevention of heart disease in women. ( Alt, S; Friedman, J; Hong, S, 2003) |
| "Venous thromboembolism is a frequent and serious disorder influenced by numerous factors." | 2.42 | Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. ( Dahl, OE; Mismetti, P; Quinlan, DJ; Rosencher, N; Samama, MM, 2003) |
| "Diabetes mellitus is another CHD risk factor which is stronger in women than in men, and CHD death rates are 3-7 times greater among diabetic than nondiabetic women." | 2.40 | Risk factors for coronary heart disease in women. ( Hennekens, CH, 1998) |
| "A computational approach involving mathematical modeling and in silico experiments was used to characterize the determinants of extent and duration of platelet cyclooxygenase (COX)-1 inhibition by aspirin and design precision dosing in patients with accelerated platelet turnover or reduced drug bioavailability." | 1.72 | Physiologically based modelling of the antiplatelet effect of aspirin: A tool to characterize drug responsiveness and inform precision dosing. ( Giaretta, A; Petrucci, G; Rocca, B; Toffolo, GM, 2022) |
| "In Western European countries, acute ischemic stroke (AIS) remains the third leading cause of death." | 1.62 | Risk factors among stroke subtypes and its impact on the clinical outcome of patients of Northern Portugal under previous aspirin therapy. ( Freitas-Silva, M; Medeiros, R; Nunes, JPL, 2021) |
| "Class 1 obesity is associated with enhanced platelet activation in response to AA in patients on dual antiplatelet therapy." | 1.62 | Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity. ( Eichelberger, B; Gremmel, T; Kopp, CW; Lee, S; Panzer, S, 2021) |
| "For ovarian cancer, there was no significant association overall (HR: 0." | 1.62 | Associations between daily aspirin use and cancer risk across strata of major cancer risk factors in two large U.S. cohorts. ( Cook, MB; Hurwitz, LM; Michels, KA; Pfeiffer, RM; Trabert, B, 2021) |
| "Aspirin treatment modified metabolites involved in suppressing lipogenesis, oxidative stress, and neoplastic formation." | 1.56 | Aspirin Modifies Inflammatory Mediators and Metabolomic Profiles and Contributes to the Suppression of Obesity-Associated Breast Cancer Cell Growth. ( Chiu, HH; Hsieh, CC; Kuo, CH; Wang, CH, 2020) |
| "Aspirin treatment reduced body weight gain, reversed glucose intolerance, and depressed hepatic lipid accumulation in female, but not in male mice." | 1.51 | Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. ( Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019) |
| ": The prevalence of hypertension, type 2 diabetes mellitus (DM2) and the metabolic syndrome continues to increase in Latin America, while the rates of diagnosis, treatment and control of these disorders remain low." | 1.51 | Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. ( Accini, JL; Alcocer, L; Barbosa, E; Camacho, PA; Cobos, L; Coca, A; Diaz, M; Lanas, F; López-Jaramillo, P; Molina, DI; Pasquel, M; Ponte-Negretti, CI; Sanchez, R; Sebba-Barroso, W; Wyss, F; Zanchetti, A, 2019) |
| "Aspirin treatment significantly prevented bone loss by increasing bone formation." | 1.43 | Aspirin prevents bone loss with little mechanical improvement in high-fat-fed ovariectomized rats. ( Cui, L; Fu, Z; Huang, J; Huang, M; Lee, WYW; Li, G; Liang, Y; Lin, S; Suen, CW; Wu, H; Wu, T; Xu, L, 2016) |
| "Obesity is a cluster of medical conditions affecting several pathophysiological processes, including platelet (PLT) function." | 1.42 | Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. ( Gąsior, Z; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia-Stec, K, 2015) |
| "Smoking, alcohol abuse, and obesity were more common in patients with ST elevation myocardial infarction (STEMI) (P < 0." | 1.42 | Management of acute coronary syndromes in a developing country; time for a paradigm shift? an observational study. ( Bandara, R; De Silva, C; Galgomuwa, MP; Medagama, A, 2015) |
| "Aspirin resistance was measured in aspirin reaction units using VerifyNow(®)." | 1.40 | Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes. ( Ahn, KJ; Cho, JH; Choi, KM; Kang, JG; Kim, JD; Kim, JH; Lee, BW; Lee, KY; Mok, JO; Moon, MK; Park, CY; Park, JY; Park, SW, 2014) |
| "Inflammation is postulated to link obesity and benign prostatic hyperplasia (BPH)." | 1.39 | Body mass index predicts failure of surgical management in benign prostatic hyperplasia. ( Dick, CP; Edwards, J; Halbert, GL; Horgan, PG; Orange, C; Qayyum, T; Underwood, MA; Walker, VC; Willder, JM, 2013) |
| "We sought to determine the prevalence of acute respiratory distress syndrome after intracerebral hemorrhage, characterize risk factors for its development, and assess its impact on patient outcomes." | 1.39 | Acute respiratory distress syndrome after spontaneous intracerebral hemorrhage*. ( Avery, L; Bajwa, E; Camargo, CA; Chang, Y; Duran-Mendicuti, MA; Elmer, J; Goldstein, JN; Greenberg, SM; Hess, DR; Hou, P; Okechukwu, I; Pallin, DJ; Pontes-Neto, O; Rosand, J; Schreiber, H; Wilcox, SR, 2013) |
| "Two SNPs in TXNRD3 were associated with rectal cancer (rs11718498 dominant OR 1." | 1.38 | Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer. ( Corcoran, C; Lundgreen, A; Slattery, ML; Welbourn, B; Wolff, RK, 2012) |
| "Vasoplegia was defined as persistent low systemic vascular resistance, despite multiple intravenous pressor drugs at high dose, between 6 and 48 hours after surgery." | 1.38 | Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era. ( Patarroyo, M; Shrestha, K; Simbaqueba, C; Smedira, N; Starling, RC; Tang, WH; Taylor, DO, 2012) |
| "Obesity is associated with inflammation." | 1.35 | The effect of anti-inflammatory (aspirin and/or statin) therapy on body weight in Type 2 diabetic individuals: EAT, a retrospective study. ( Boaz, M; Lisy, L; Wainstein, J; Zandman-Goddard, G, 2009) |
| "NSAID use was unrelated to risk of endometrial cancer in both obese and nonobese women." | 1.35 | Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. ( Bodelon, C; Chen, C; Doherty, JA; Rossing, MA; Weiss, NS, 2009) |
| "The progress of leukoaraiosis is greatly inhibited by long-term correction of platelet hyper-aggregability." | 1.33 | Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability. ( Fujita, S; Fukushima, K; Kawaguchi, T; Uehara, T, 2005) |
| "But aspirin therapy was used in only 35 cases (32." | 1.33 | The rate of checking urine microalbumin and aspirin primary prevention in type 2 DM. ( Limpawattana, P; Mahankkanukrauh, A; Sawanyawisuth, K; Wongvipaporn, C, 2006) |
| "Overweight and obesity are well-established risk factors for cardiovascular disease and decline in kidney function in individuals with existing chronic kidney disease (CKD)." | 1.33 | Association between body mass index and CKD in apparently healthy men. ( Buring, JE; Gaziano, JM; Gelber, RP; Kausz, AT; Kurth, T; Levey, AS; Manson, JE, 2005) |
| "Only clonidine treatment totally prevented the development of insulin resistance, and high-dose aspirin, known to prevent insulin resistance by inhibition of the activity of IkappaB kinase-beta, decreased the degree of insulin resistance by almost 70%." | 1.32 | Hypertension and insulin resistance are not directly related in obese dogs. ( Gokee, A; Rocchini, AP; Yang, JQ, 2004) |
| "Aspirin was used regularly by 37% of those with CVD and by 13% of those with risk factors only Adjusted odds of regular aspirin use were significantly greater for individuals with CVD than for those with one CVD risk factor (odds ratio [OR] = 4." | 1.31 | Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. ( Fagot-Campagna, A; Narayan, KM; Rolka, DB, 2001) |
| " During long-term therapy, salicylate dosage for obese individuals should not be adjusted upward in proportion to total weight." | 1.27 | Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. ( Abernethy, DR; Boxenbaum, HG; Greenblatt, DJ; Harmatz, JS; Matlis, R; Ochs, HR; Shader, RI, 1986) |
| "The uric acid clearance were 5." | 1.26 | Renal excretion of uric acid during prolonged fasting. ( Fox, IH; Goldstein, MB; Halperin, ML; Marliss, ER, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (8.70) | 18.7374 |
| 1990's | 18 (11.18) | 18.2507 |
| 2000's | 49 (30.43) | 29.6817 |
| 2010's | 56 (34.78) | 24.3611 |
| 2020's | 24 (14.91) | 2.80 |
| Authors | Studies |
|---|---|
| Ray, JG | 1 |
| Abdulaziz, KE | 1 |
| Berger, H | 1 |
| Puccini, M | 1 |
| Rauch, C | 1 |
| Jakobs, K | 1 |
| Friebel, J | 1 |
| Hassanein, A | 1 |
| Landmesser, U | 1 |
| Rauch, U | 1 |
| Yun, B | 1 |
| Ahn, SH | 1 |
| Yoon, JH | 1 |
| Kim, BK | 1 |
| Sun, X | 1 |
| Wang, F | 1 |
| Liu, J | 2 |
| Wu, L | 1 |
| Wang, Z | 2 |
| Chen, X | 1 |
| Wang, M | 1 |
| Zeng, Q | 1 |
| Roy, S | 1 |
| Bhowmik, DR | 1 |
| Begum, R | 1 |
| Amin, MT | 1 |
| Islam, MA | 1 |
| Ahmed, F | 1 |
| Hossain, MS | 1 |
| Giaretta, A | 1 |
| Petrucci, G | 1 |
| Rocca, B | 2 |
| Toffolo, GM | 1 |
| Won, KB | 1 |
| Shin, ES | 1 |
| Kang, J | 1 |
| Yang, HM | 1 |
| Park, KW | 1 |
| Han, KR | 1 |
| Moon, KW | 1 |
| Oh, SK | 1 |
| Kim, U | 1 |
| Rhee, MY | 1 |
| Kim, DI | 1 |
| Kim, SY | 1 |
| Lee, SY | 1 |
| Han, JK | 1 |
| Koo, BK | 1 |
| Kim, HS | 1 |
| Davis, JS | 1 |
| Chavez, JC | 1 |
| Kok, M | 1 |
| San Miguel, Y | 1 |
| Lee, HY | 1 |
| Henderson, H | 1 |
| Overman, MJ | 1 |
| Morris, V | 1 |
| Kee, B | 1 |
| Fogelman, D | 1 |
| Advani, SM | 1 |
| Johnson, B | 1 |
| Parseghian, C | 1 |
| Shen, JP | 1 |
| Dasari, A | 1 |
| Shaw, KR | 1 |
| Vilar, E | 1 |
| Raghav, KP | 1 |
| Shureiqi, I | 1 |
| Wolff, RA | 1 |
| Meric-Bernstam, F | 1 |
| Maru, D | 1 |
| Menter, DG | 1 |
| Kopetz, S | 1 |
| Chang, S | 1 |
| Nay, I | 1 |
| Hutchinson, D | 1 |
| Rondina, M | 1 |
| Kim, K | 1 |
| Kroencke, R | 1 |
| Kirkham, A | 1 |
| Trujillo, T | 1 |
| Tolley, ND | 1 |
| Munger, M | 1 |
| Muldoon, KA | 1 |
| McLean, C | 1 |
| El-Chaár, D | 1 |
| Corsi, DJ | 1 |
| Rybak, N | 1 |
| Dagvadorj, A | 1 |
| Guo, Y | 2 |
| Rennicks White, R | 1 |
| Dingwall-Harvey, ALJ | 1 |
| Gaudet, LM | 1 |
| Walker, MC | 1 |
| Wen, SW | 1 |
| Loomans-Kropp, HA | 2 |
| Umar, A | 2 |
| Robillard, PY | 1 |
| Dekker, G | 1 |
| Scioscia, M | 1 |
| Bonsante, F | 1 |
| Boukerrou, M | 1 |
| Iacobelli, S | 1 |
| Tran, PL | 1 |
| Zhang, J | 1 |
| Wang, A | 1 |
| Tian, X | 1 |
| Meng, X | 1 |
| Xie, X | 1 |
| Jing, J | 1 |
| Lin, J | 1 |
| Wang, Y | 3 |
| Li, Z | 1 |
| Liu, L | 1 |
| Li, H | 1 |
| Jiang, Y | 1 |
| Zhao, X | 1 |
| Pinsky, P | 1 |
| Cao, Y | 1 |
| Chan, AT | 3 |
| Chen, Z | 1 |
| Mo, J | 1 |
| Schlemm, L | 1 |
| Schlemm, E | 1 |
| Moyad, MA | 2 |
| Hsieh, CC | 1 |
| Chiu, HH | 1 |
| Wang, CH | 1 |
| Kuo, CH | 1 |
| Simon, TG | 1 |
| Hurwitz, LM | 1 |
| Michels, KA | 1 |
| Cook, MB | 1 |
| Pfeiffer, RM | 1 |
| Trabert, B | 1 |
| Sardi, C | 1 |
| Martini, E | 1 |
| Mello, T | 1 |
| Camelliti, S | 1 |
| Sfondrini, L | 1 |
| Marcucci, F | 1 |
| Kallikourdis, M | 1 |
| Sommariva, M | 1 |
| Rumio, C | 1 |
| Lee, S | 1 |
| Eichelberger, B | 1 |
| Kopp, CW | 1 |
| Panzer, S | 1 |
| Gremmel, T | 1 |
| Freitas-Silva, M | 1 |
| Medeiros, R | 1 |
| Nunes, JPL | 1 |
| Kim, BS | 1 |
| Chan, N | 1 |
| Hsu, G | 1 |
| Makaryus, AN | 1 |
| Chopra, M | 1 |
| Cohen, SL | 1 |
| Makaryus, JN | 1 |
| Chiang, KC | 1 |
| Gupta, A | 1 |
| Norgard, NB | 1 |
| Wang, T | 1 |
| Parada, H | 1 |
| McClain, KM | 1 |
| Bradshaw, PT | 1 |
| Terry, MB | 1 |
| Teitelbaum, SL | 1 |
| Neugut, AI | 1 |
| Gammon, MD | 1 |
| Wang, X | 2 |
| Slattery, ML | 2 |
| Chang-Claude, J | 1 |
| Potter, JD | 1 |
| Gallinger, S | 1 |
| Caan, B | 1 |
| Lampe, JW | 1 |
| Newcomb, PA | 1 |
| Zubair, N | 1 |
| Hsu, L | 1 |
| Schoen, RE | 1 |
| Hoffmeister, M | 1 |
| Brenner, H | 1 |
| Le Marchand, L | 1 |
| Peters, U | 1 |
| White, E | 1 |
| Scherzer, R | 1 |
| Grayson, MH | 1 |
| Zhou, Y | 1 |
| Peng, H | 1 |
| Liu, Z | 1 |
| Zhang, KK | 1 |
| Jendrusch, C | 1 |
| Drake, M | 1 |
| Hao, Y | 1 |
| Xie, L | 1 |
| López-Jaramillo, P | 1 |
| Barbosa, E | 1 |
| Molina, DI | 1 |
| Sanchez, R | 1 |
| Diaz, M | 1 |
| Camacho, PA | 1 |
| Lanas, F | 1 |
| Pasquel, M | 1 |
| Accini, JL | 1 |
| Ponte-Negretti, CI | 1 |
| Alcocer, L | 1 |
| Cobos, L | 1 |
| Wyss, F | 1 |
| Sebba-Barroso, W | 1 |
| Coca, A | 1 |
| Zanchetti, A | 1 |
| Stevenson, JC | 1 |
| Mogabgab, O | 1 |
| Wiviott, SD | 1 |
| Antman, EM | 1 |
| Foody, JM | 1 |
| Wang, TY | 1 |
| Sabatine, MS | 1 |
| Cannon, CP | 1 |
| Li, S | 1 |
| Giugliano, RP | 1 |
| Gao, F | 1 |
| Men, J | 1 |
| Yang, J | 1 |
| Modi, P | 1 |
| Wei, M | 1 |
| Kautzky-Willer, A | 1 |
| Stich, K | 1 |
| Hintersteiner, J | 1 |
| Kautzky, A | 1 |
| Kamyar, MR | 1 |
| Saukel, J | 1 |
| Johnson, J | 1 |
| Lemmens-Gruber, R | 1 |
| Elmer, J | 1 |
| Hou, P | 1 |
| Wilcox, SR | 1 |
| Chang, Y | 1 |
| Schreiber, H | 1 |
| Okechukwu, I | 1 |
| Pontes-Neto, O | 1 |
| Bajwa, E | 1 |
| Hess, DR | 1 |
| Avery, L | 1 |
| Duran-Mendicuti, MA | 1 |
| Camargo, CA | 1 |
| Greenberg, SM | 1 |
| Rosand, J | 1 |
| Pallin, DJ | 1 |
| Goldstein, JN | 1 |
| Stolarz-Skrzypek, K | 1 |
| Bednarski, A | 1 |
| Drozdz, D | 1 |
| Czarnecka, D | 1 |
| Kawai, VK | 1 |
| Avalos, I | 1 |
| Oeser, A | 1 |
| Oates, JA | 1 |
| Milne, GL | 1 |
| Solus, JF | 1 |
| Chung, CP | 1 |
| Stein, CM | 1 |
| Chakraborty, P | 1 |
| Banerjee, S | 1 |
| Saha, P | 1 |
| Nandi, SS | 1 |
| Sharma, S | 1 |
| Goswami, SK | 1 |
| Chakravarty, B | 1 |
| Kabir, SN | 1 |
| Prandoni, P | 1 |
| Barbar, S | 1 |
| Milan, M | 1 |
| Vedovetto, V | 1 |
| Pesavento, R | 1 |
| Darlington, A | 1 |
| Tello-Montoliu, A | 1 |
| Rollini, F | 1 |
| Ueno, M | 1 |
| Ferreiro, JL | 1 |
| Patel, R | 1 |
| Desai, B | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Angiolillo, DJ | 1 |
| Lackland, DT | 1 |
| Roccella, EJ | 1 |
| Deutsch, AF | 1 |
| Fornage, M | 1 |
| George, MG | 1 |
| Howard, G | 1 |
| Kissela, BM | 1 |
| Kittner, SJ | 1 |
| Lichtman, JH | 1 |
| Lisabeth, LD | 1 |
| Schwamm, LH | 1 |
| Smith, EE | 1 |
| Towfighi, A | 1 |
| Joseph, JJ | 1 |
| Golden, SH | 1 |
| Kim, JD | 1 |
| Park, CY | 1 |
| Ahn, KJ | 1 |
| Cho, JH | 1 |
| Choi, KM | 1 |
| Kang, JG | 1 |
| Kim, JH | 1 |
| Lee, KY | 1 |
| Lee, BW | 1 |
| Mok, JO | 1 |
| Moon, MK | 1 |
| Park, JY | 1 |
| Park, SW | 2 |
| Cantu, JA | 1 |
| Jauk, VR | 1 |
| Owen, J | 1 |
| Biggio, JR | 1 |
| Abramovici, AR | 1 |
| Edwards, RK | 1 |
| Tita, AT | 1 |
| Daels, FP | 1 |
| Gaizauskas, A | 1 |
| Rioja, J | 1 |
| Varshney, AK | 1 |
| Erkan, E | 1 |
| Ozgok, Y | 1 |
| Melekos, M | 1 |
| de la Rosette, JJ | 1 |
| Murali, SB | 1 |
| Siasos, G | 1 |
| Oikonomou, E | 1 |
| Zaromitidou, M | 1 |
| Kioufis, S | 1 |
| Kokkou, E | 1 |
| Mourouzis, K | 1 |
| Vlasis, K | 1 |
| Vavuranakis, M | 1 |
| Stone, PH | 1 |
| Papavassiliou, AG | 1 |
| Tousoulis, D | 1 |
| Haberka, M | 1 |
| Mizia-Stec, K | 1 |
| Lasota, B | 1 |
| Kyrcz-Krzemień, S | 1 |
| Gąsior, Z | 1 |
| Movahedi, M | 1 |
| Bishop, DT | 1 |
| Macrae, F | 1 |
| Mecklin, JP | 1 |
| Moeslein, G | 1 |
| Olschwang, S | 1 |
| Eccles, D | 1 |
| Evans, DG | 1 |
| Maher, ER | 1 |
| Bertario, L | 1 |
| Bisgaard, ML | 1 |
| Dunlop, MG | 1 |
| Ho, JW | 1 |
| Hodgson, SV | 1 |
| Lindblom, A | 1 |
| Lubinski, J | 1 |
| Morrison, PJ | 1 |
| Murday, V | 1 |
| Ramesar, RS | 1 |
| Side, L | 1 |
| Scott, RJ | 1 |
| Thomas, HJ | 1 |
| Vasen, HF | 1 |
| Burn, J | 1 |
| Mathers, JC | 1 |
| Mani, H | 1 |
| Ahluwalia, S | 1 |
| Medagama, A | 1 |
| Bandara, R | 1 |
| De Silva, C | 1 |
| Galgomuwa, MP | 1 |
| Rubino, F | 1 |
| Matsuo, K | 1 |
| Cahoon, SS | 1 |
| Yoshihara, K | 1 |
| Shida, M | 1 |
| Kakuda, M | 1 |
| Adachi, S | 1 |
| Moeini, A | 1 |
| Machida, H | 1 |
| Garcia-Sayre, J | 1 |
| Ueda, Y | 1 |
| Enomoto, T | 1 |
| Mikami, M | 1 |
| Roman, LD | 1 |
| Sood, AK | 1 |
| von Dadelszen, P | 1 |
| Magee, LA | 1 |
| Lin, S | 1 |
| Lee, WYW | 1 |
| Huang, M | 2 |
| Fu, Z | 1 |
| Liang, Y | 1 |
| Wu, H | 1 |
| Xu, L | 1 |
| Suen, CW | 1 |
| Huang, J | 1 |
| Wu, T | 1 |
| Cui, L | 1 |
| Li, G | 1 |
| Ladapo, JA | 1 |
| Hoffmann, U | 1 |
| Lee, KL | 1 |
| Coles, A | 1 |
| Mark, DB | 1 |
| Dolor, RJ | 1 |
| Pelberg, RA | 1 |
| Budoff, M | 1 |
| Sigurdsson, G | 1 |
| Severance, HW | 1 |
| Douglas, PS | 1 |
| Patrono, C | 1 |
| Schrier, RW | 1 |
| Bogaert, YE | 1 |
| Barton, JR | 1 |
| Sibai, BM | 2 |
| Jang, AS | 1 |
| Park, JS | 1 |
| Kim, DJ | 1 |
| Uh, ST | 1 |
| Seo, KH | 1 |
| Kim, YH | 1 |
| Park, HS | 1 |
| Park, CS | 1 |
| Ogston, NC | 1 |
| Karastergiou, K | 1 |
| Hosseinzadeh-Attar, MJ | 1 |
| Bhome, R | 1 |
| Madani, R | 1 |
| Stables, M | 1 |
| Gilroy, D | 1 |
| Flachs, P | 1 |
| Hensler, M | 1 |
| Kopecky, J | 1 |
| Mohamed-Ali, V | 1 |
| Federman, DG | 1 |
| Shelling, M | 1 |
| Prodanovich, S | 1 |
| Gunderson, CG | 1 |
| Kirsner, RS | 1 |
| Boaz, M | 1 |
| Lisy, L | 1 |
| Zandman-Goddard, G | 1 |
| Wainstein, J | 1 |
| Wang, ZJ | 1 |
| Zhou, YJ | 1 |
| Liu, YY | 1 |
| Yu, M | 1 |
| Shi, DM | 1 |
| Zhao, YX | 1 |
| Guo, YH | 1 |
| Cheng, WJ | 1 |
| Nie, B | 1 |
| Ge, HL | 1 |
| Jia, DA | 1 |
| Yang, SW | 1 |
| Yan, ZX | 1 |
| Carvalho-Filho, MA | 1 |
| Ropelle, ER | 1 |
| Pauli, RJ | 1 |
| Cintra, DE | 1 |
| Tsukumo, DM | 1 |
| Silveira, LR | 1 |
| Curi, R | 1 |
| Carvalheira, JB | 1 |
| Velloso, LA | 1 |
| Saad, MJ | 1 |
| Pretorius, M | 1 |
| Brown, NJ | 1 |
| Bodelon, C | 1 |
| Doherty, JA | 1 |
| Chen, C | 1 |
| Rossing, MA | 1 |
| Weiss, NS | 1 |
| Diehl, P | 1 |
| Olivier, C | 1 |
| Halscheid, C | 1 |
| Helbing, T | 1 |
| Bode, C | 2 |
| Moser, M | 3 |
| Bordeaux, BC | 1 |
| Qayyum, R | 1 |
| Yanek, LR | 1 |
| Vaidya, D | 1 |
| Becker, LC | 1 |
| Faraday, N | 1 |
| Becker, DM | 1 |
| Ertugrul, DT | 1 |
| Tutal, E | 1 |
| Yildiz, M | 1 |
| Akin, O | 1 |
| Yalçin, AA | 1 |
| Ure, OS | 1 |
| Yilmaz, H | 1 |
| Yavuz, B | 1 |
| Deveci, OS | 1 |
| Ata, N | 1 |
| Küçükazman, M | 1 |
| Campos-Outcalt, D | 1 |
| Ahmad, T | 1 |
| Chasman, DI | 1 |
| Mora, S | 1 |
| Paré, G | 1 |
| Cook, NR | 1 |
| Buring, JE | 3 |
| Ridker, PM | 2 |
| Lee, IM | 1 |
| Nagler, M | 1 |
| Haslauer, M | 1 |
| Wuillemin, WA | 1 |
| Scholl, S | 1 |
| Dellon, ES | 1 |
| Shaheen, NJ | 1 |
| Hoshida, S | 1 |
| Yuasa, F | 1 |
| Lim, YJ | 1 |
| Kijima, Y | 1 |
| Iwasaka, J | 1 |
| Iwasaka, T | 1 |
| Santilli, F | 1 |
| Vazzana, N | 1 |
| Liani, R | 1 |
| Guagnano, MT | 1 |
| Davì, G | 1 |
| Fukutomi, Y | 1 |
| Taniguchi, M | 1 |
| Tsuburai, T | 1 |
| Tanimoto, H | 1 |
| Oshikata, C | 1 |
| Ono, E | 1 |
| Sekiya, K | 1 |
| Higashi, N | 1 |
| Mori, A | 1 |
| Hasegawa, M | 1 |
| Nakamura, H | 1 |
| Akiyama, K | 1 |
| Patarroyo, M | 1 |
| Simbaqueba, C | 1 |
| Shrestha, K | 1 |
| Starling, RC | 1 |
| Smedira, N | 1 |
| Tang, WH | 1 |
| Taylor, DO | 1 |
| Ahmed, RM | 1 |
| Moustafa, MS | 1 |
| Shawky, KM | 1 |
| Samir, NE | 1 |
| Nour El Din, HA | 1 |
| Hassan, el BM | 1 |
| Blackler, R | 1 |
| Syer, S | 1 |
| Bolla, M | 1 |
| Ongini, E | 1 |
| Wallace, JL | 1 |
| Lundgreen, A | 1 |
| Welbourn, B | 1 |
| Corcoran, C | 1 |
| Wolff, RK | 1 |
| Schenk, JM | 1 |
| Calip, GS | 1 |
| Tangen, CM | 1 |
| Goodman, P | 1 |
| Parsons, JK | 1 |
| Thompson, IM | 1 |
| Kristal, AR | 1 |
| Neill, AS | 1 |
| Nagle, CM | 1 |
| Protani, MM | 1 |
| Obermair, A | 1 |
| Spurdle, AB | 1 |
| Webb, PM | 1 |
| Levy, IG | 1 |
| Pim, CP | 1 |
| Suh, S | 1 |
| Seo, PJ | 1 |
| Park, H | 1 |
| Shin, CM | 1 |
| Jo, HJ | 1 |
| Kim, HY | 1 |
| Lee, SH | 1 |
| Park, YS | 1 |
| Hwang, JH | 1 |
| Kim, JW | 1 |
| Jeong, SH | 1 |
| Kim, N | 1 |
| Lee, DH | 1 |
| Song, IS | 1 |
| Jung, HC | 1 |
| Willder, JM | 1 |
| Walker, VC | 1 |
| Halbert, GL | 1 |
| Dick, CP | 1 |
| Orange, C | 1 |
| Qayyum, T | 1 |
| Horgan, PG | 1 |
| Underwood, MA | 1 |
| Edwards, J | 1 |
| Gao, W | 1 |
| Zhang, Q | 1 |
| Ge, H | 1 |
| Zhou, Z | 1 |
| Kheradmand, F | 1 |
| Rishi, K | 1 |
| Corry, DB | 1 |
| Hall, M | 1 |
| McGettigan, M | 1 |
| O'Callaghan, P | 1 |
| Graham, I | 1 |
| Shelley, E | 1 |
| Feely, J | 1 |
| Lawlor, DA | 1 |
| Bedford, C | 1 |
| Taylor, M | 1 |
| Ebrahim, S | 1 |
| Jungmann, E | 1 |
| Tamminen, M | 1 |
| Lassila, R | 1 |
| Westerbacka, J | 1 |
| Vehkavaara, S | 1 |
| Yki-Järvinen, H | 1 |
| Talbert, RL | 1 |
| Pieper, JA | 1 |
| Ito, MK | 1 |
| SMITH, LB | 1 |
| Sacco, M | 1 |
| Pellegrini, F | 1 |
| Roncaglioni, MC | 1 |
| Avanzini, F | 1 |
| Tognoni, G | 1 |
| Nicolucci, A | 1 |
| Hong, S | 1 |
| Friedman, J | 1 |
| Alt, S | 1 |
| Samama, MM | 1 |
| Dahl, OE | 1 |
| Quinlan, DJ | 1 |
| Mismetti, P | 1 |
| Rosencher, N | 1 |
| Rocchini, AP | 1 |
| Yang, JQ | 1 |
| Gokee, A | 1 |
| Michaud, DS | 1 |
| Critchley, J | 1 |
| Zhao, D | 1 |
| Wei, W | 1 |
| Capewell, S | 1 |
| Löbner, K | 1 |
| Füchtenbusch, M | 1 |
| Gohlke, H | 1 |
| Papp, E | 1 |
| Havasi, V | 1 |
| Bene, J | 1 |
| Komlosi, K | 1 |
| Czopf, L | 1 |
| Magyar, E | 1 |
| Feher, C | 1 |
| Feher, G | 1 |
| Horvath, B | 1 |
| Marton, Z | 1 |
| Alexy, T | 1 |
| Habon, T | 1 |
| Szabo, L | 1 |
| Toth, K | 1 |
| Melegh, B | 1 |
| Schaerlig, E | 1 |
| Gelber, RP | 1 |
| Kurth, T | 1 |
| Kausz, AT | 1 |
| Manson, JE | 3 |
| Levey, AS | 1 |
| Gaziano, JM | 1 |
| Fujita, S | 1 |
| Kawaguchi, T | 1 |
| Uehara, T | 1 |
| Fukushima, K | 1 |
| Marissal, JP | 1 |
| Sailly, JC | 1 |
| Crainich, D | 1 |
| Lebrun, T | 1 |
| Falkner, B | 1 |
| Weber, MA | 1 |
| Keilson, LM | 1 |
| Gogia, A | 1 |
| Agarwal, PK | 1 |
| Haines, ST | 1 |
| Fuke, DC | 1 |
| Lender, D | 1 |
| Rodgers, PT | 1 |
| Sysko, SK | 1 |
| Zhang, L | 1 |
| Zheng, J | 1 |
| Li, HM | 1 |
| Meng, YX | 1 |
| Sawanyawisuth, K | 1 |
| Limpawattana, P | 1 |
| Mahankkanukrauh, A | 1 |
| Wongvipaporn, C | 1 |
| Kakafika, AI | 1 |
| Liberopoulos, EN | 1 |
| Karagiannis, A | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Kurukulasuriya, LR | 1 |
| Govindarajan, G | 1 |
| Sowers, J | 1 |
| Lewis, JD | 1 |
| Schinnar, R | 1 |
| Bilker, WB | 1 |
| Strom, BL | 1 |
| Kotake, H | 1 |
| Oikawa, S | 1 |
| Yusuf, S | 1 |
| Fallen, E | 1 |
| Harrington, RA | 2 |
| Guyton, RA | 1 |
| Füessl, HS | 1 |
| Di Renzo, L | 1 |
| Noce, A | 1 |
| De Angelis, S | 1 |
| Miani, N | 1 |
| Di Daniele, N | 1 |
| Tozzo, C | 1 |
| De Lorenzo, A | 1 |
| Robles-Díaz, G | 1 |
| Fastag, D | 1 |
| Varas-Lorenzo, C | 1 |
| Castellsague, J | 1 |
| Stang, MR | 1 |
| Tomas, L | 1 |
| Aguado, J | 1 |
| Perez-Gutthann, S | 1 |
| Kornitzer, M | 1 |
| Borow, M | 1 |
| Goldson, H | 1 |
| Lilavivathana, U | 1 |
| Brodows, RG | 1 |
| Bronner, LL | 1 |
| Kanter, DS | 1 |
| Gordon, T | 1 |
| Thom, E | 1 |
| Caritis, SN | 1 |
| Klebanoff, M | 1 |
| McNellis, D | 1 |
| Paul, RH | 1 |
| Geissler, CA | 3 |
| Daly, PA | 2 |
| Krieger, DR | 2 |
| Dulloo, AG | 3 |
| Young, JB | 2 |
| Landsberg, L | 2 |
| Horton, TJ | 2 |
| Bowker, TJ | 1 |
| Clayton, TC | 1 |
| Ingham, J | 1 |
| McLennan, NR | 1 |
| Hobson, HL | 1 |
| Pyke, SD | 1 |
| Schofield, B | 1 |
| Wood, DA | 1 |
| Gillum, RF | 1 |
| Gascón Ramón, G | 1 |
| Bertomeu i Blanch, F | 1 |
| Baño Aracil, M | 1 |
| Madrigal, JA | 1 |
| Shekhtman, MM | 1 |
| Rasul'-Zade, IuG | 1 |
| Hennekens, CH | 2 |
| Nordt, TK | 1 |
| Kohler, B | 1 |
| Ruef, J | 1 |
| Peter, K | 1 |
| Kübler, W | 1 |
| Mahaffey, KW | 1 |
| Simoons, ML | 1 |
| Granger, CB | 1 |
| Graffagnino, C | 1 |
| Alberts, MJ | 1 |
| Laskowitz, DT | 1 |
| Miller, JM | 1 |
| Sloan, MA | 1 |
| Berdan, LG | 1 |
| MacAulay, CM | 1 |
| Lincoff, AM | 1 |
| Deckers, J | 1 |
| Topol, EJ | 1 |
| Califf, RM | 1 |
| Dyck, DJ | 1 |
| Rolka, DB | 1 |
| Fagot-Campagna, A | 1 |
| Narayan, KM | 1 |
| Cohen, JD | 1 |
| Yuan, M | 1 |
| Konstantopoulos, N | 1 |
| Lee, J | 1 |
| Hansen, L | 1 |
| Li, ZW | 1 |
| Karin, M | 1 |
| Shoelson, SE | 1 |
| Weisser, B | 1 |
| Düsing, R | 1 |
| Mengden, T | 1 |
| Abramson, B | 1 |
| de Ferranti, S | 1 |
| Rifai, N | 1 |
| Kather, H | 1 |
| Walter, E | 1 |
| Simon, B | 1 |
| Debons, AF | 1 |
| Krimsky, I | 1 |
| Maayan, ML | 1 |
| Fani, K | 1 |
| Jemenez, FA | 1 |
| Prof Aiuto, G | 1 |
| Fox, IH | 1 |
| Halperin, ML | 1 |
| Goldstein, MB | 1 |
| Marliss, ER | 1 |
| Tosteson, H | 1 |
| Satterfield, S | 1 |
| Hebert, P | 1 |
| O'Connor, GT | 1 |
| Marks, JW | 1 |
| Bonorris, GG | 1 |
| Schoenfield, LJ | 1 |
| Ransil, BJ | 1 |
| Lavie, CJ | 1 |
| Squires, RW | 1 |
| Gau, GT | 1 |
| Greenblatt, DJ | 1 |
| Abernethy, DR | 1 |
| Boxenbaum, HG | 1 |
| Matlis, R | 1 |
| Ochs, HR | 1 |
| Harmatz, JS | 1 |
| Shader, RI | 1 |
| Miller, DS | 1 |
| Moss, GD | 1 |
| Chmell, S | 1 |
| Pillars, JR | 1 |
| Haid, S | 1 |
| Milewski, S | 1 |
| Kågedal, B | 1 |
| Laurell, S | 1 |
| Rooth, G | 1 |
| Shagrin, JW | 1 |
| Frame, B | 1 |
| Duncan, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vascular Damage in Systemic Lupus Erythematosus (SLE)[NCT00731302] | Phase 1 | 70 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients[NCT02933788] | Phase 4 | 116 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| PROspective Multicenter Imaging Study for Evaluation of Chest Pain - The PROMISE Trial[NCT01174550] | 10,003 participants (Actual) | Interventional | 2010-07-31 | Completed | |||
| Renin-Angiotensin Aldosterone System and Fibrinolysis(RAAS) Interaction in Humans- Specific Aim 3[NCT00685945] | 24 participants (Actual) | Interventional | 2007-12-31 | Completed | |||
| Prevention of Females Malignancies in Families With Hereditary Breast Cancer by Personalized Optimization of Se Levels in the Organism.[NCT04014283] | 7,000 participants (Anticipated) | Interventional | 2014-10-31 | Active, not recruiting | |||
| Efficacy of Medifast's 5 & 1 Program Compared to a Food-based Diet After a Period of Weight Loss and Weight Maintenance[NCT01011491] | 90 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cumulative radiation exposure from all cardiovascular diagnostic tests and procedures performed within 90 days after randomization. (NCT01174550)
Timeframe: 90 days
| Intervention | milliSievert (mSv) (Median) |
|---|---|
| Anatomic Diagnostic Test | 10.0 |
| Functional Diagnostic Tests | 11.3 |
Percentage of Invasive Cardiac Catheterization Events Without Obstructive Coronary Artery Disease (CAD)Within 90 Days Following Participant Randomization (NCT01174550)
Timeframe: Up to 90 days following participant randomization
| Intervention | Percentage of events (Mean) |
|---|---|
| Anatomic Diagnostic Test | 3.4 |
| Functional Diagnostic Tests | 4.3 |
Assess and compare total medical cost for the two diagnostic testing arms by intention to treat at both 90 days and 3 years cumulative. (NCT01174550)
Timeframe: 90 days and 3 years cumulative
| Intervention | Per participant cost in US dollars (Mean) | |
|---|---|---|
| 90 days | 3 years cumulative | |
| Anatomic Diagnostic Test | 2494 | 7213 |
| Functional Diagnostic Tests | 2240 | 6586 |
Percentage of participants with improvement in Quality of Life as measured by complete resolution of the symptoms that led to initial testing (NCT01174550)
Timeframe: 6 month, 12 month 24 month
| Intervention | % of participants (Number) | ||
|---|---|---|---|
| 6 months | 12 months | 24 months | |
| Anatomic Diagnostic Test | 43.3 | 47.3 | 52.1 |
| Functional Diagnostic Tests | 46.5 | 48.8 | 54.3 |
Participant score in Quality of Life as measured by Duke Activity Status Index (DASI). DASI measures a person's functional capacity based on a 12-item questionnaire that correlates with peak O2 uptake during exercise testing. The DASI is a self-administered questionnaire that measures a patient's functional capacity. It can be used to get a rough estimate of a patient's peak oxygen uptake. The maximum score for the DASI is 58.2 (better functional ability/capacity) and the minimum score is 0 (worse functional ability/capacity). (NCT01174550)
Timeframe: Baseline, 6 months, 12 months 24 months
| Intervention | participant score (Median) | |||
|---|---|---|---|---|
| Baseline | 6 months | 12 months | 24 months | |
| Anatomic Diagnostic Test | 21.5 | 30.5 | 29.2 | 31.5 |
| Functional Diagnostic Tests | 22.9 | 30.2 | 31.2 | 31.2 |
Participant score Quality of Life measured by Seattle Angina Scale Anginal Frequency Subscale utilizing the Seattle Angina Questionnaire (SAQ). SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease: Anginal Stability: whether symptoms are changing. Anginal Frequency: how often patient having symptoms Physical Limitation: how much condition hampers ability to do what he wants.Treatment Satisfaction: how well patient understands care. Disease Perception: impact of condition on interpersonal relationships. Each dimension assigns response an value, beginning with 1 for response at the lowest level of functioning & summing across items within each of the 5 scales. Scale scores transformed to 0-100 range by subtracting the lowest scale. Higher score suggest symptoms more stable & less frequent, condition has less impact on activities, increased satisfaction with treatment, & perception of disease has less impact on interpersonal relationships. (NCT01174550)
Timeframe: Baseline, 6 month, 12 month, 24 month
| Intervention | participant score (Median) | |||
|---|---|---|---|---|
| Baseline | 6 month | 12 month | 24 month | |
| Anatomic Diagnostic Test | 70 | 100 | 100 | 100 |
| Functional Diagnostic Tests | 80 | 100 | 100 | 100 |
Participant score Quality of Life measured by Seattle Angina Scale Anginal Frequency Subscale utilizing the Seattle Angina Questionnaire (SAQ). SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease: Anginal Stability: whether symptoms are changing. Anginal Frequency: how often patient having symptoms Physical Limitation: how much condition hampers ability to do what he wants.Treatment Satisfaction: how well patient understands care. Disease Perception: impact of condition on interpersonal relationships. Each dimension assigns response an value, beginning with 1 for response at the lowest level of functioning & summing across items within each of the 5 scales. Scale scores transformed to 0-100 range by subtracting the lowest scale. Higher score suggest symptoms more stable & less frequent, condition has less impact on activities, increased satisfaction with treatment, & perception of disease has less impact on interpersonal relationships. (NCT01174550)
Timeframe: Baseline, 6 months, 12 months, 24 months
| Intervention | participant score (Median) | |||
|---|---|---|---|---|
| Baseline | 6 month | 12 month | 24 month | |
| Anatomic Diagnostic Test | 58.3 | 83.3 | 83.3 | 91.7 |
| Functional Diagnostic Tests | 58.3 | 83.3 | 91.7 | 91.7 |
Time to this secondary endpoint as defined as a composite of death and myocardial infarction (MI). The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months
| Intervention | Percentage of participants with an event (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 90 Days | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months | 42 months | |
| Anatomic Diagnostic Test | 0.3 | 0.4 | 0.8 | 1.3 | 1.7 | 2.2 | 3.3 | 3.9 |
| Functional Diagnostic Tests | 0.6 | 0.9 | 1.2 | 1.8 | 2.0 | 2.7 | 3.0 | 4.2 |
Time to primary endpoint as defined as a composite of death, myocardial infarction (MI), major complications from cardiovascular (CV) procedures or testing, unstable angina hospitalization, and no coronary artery disease (CAD). The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months
| Intervention | Percentage of participants with an event (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 90 days | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months | 42 months | |
| Anatomic Diagnostic Test | 4.4 | 4.6 | 5.2 | 5.9 | 6.3 | 6.9 | 8.0 | 8.7 |
| Functional Diagnostic Tests | 5.2 | 5.6 | 6.1 | 6.7 | 6.9 | 7.6 | 7.9 | 9.1 |
Time to this secondary endpoint as defined as a composite of death, myocardial infarction (MI), and unstable angina hospitalization. The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months
| Intervention | Percentage of participants with an event (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 90 day | 6 month | 12 month | 18 month | 24 month | 30 month | 36 month | 42 month | |
| Anatomic Diagnostic Test | 0.9 | 1.2 | 1.8 | 2.5 | 2.9 | 3.5 | 4.6 | 5.2 |
| Functional Diagnostic Tests | 1.0 | 1.4 | 1.9 | 2.5 | 2.8 | 3.4 | 3.7 | 5.1 |
Time to this secondary endpoint as defined as a composite of major complications from cardiovascular procedures and testing (stroke, bleeding, anaphylaxis, renal failure). The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months
| Intervention | Percentage of participants with an event (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 90 day | 6 month | 12 month | 18 month | 24 month | 30 month | 36 month | 42 month | |
| Anatomic Diagnostic Test | 0.1 | 0.2 | 0.5 | 1.0 | 1.2 | 1.7 | 2.6 | 3.1 |
| Functional Diagnostic Tests | 0.3 | 0.5 | 0.8 | 1.1 | 1.4 | 1.9 | 2.2 | 3.2 |
Time to primary endpoint as defined as a composite of death, myocardial infarction (MI), major complications from cardiovascular (CV) procedures or testing, and unstable angina hospitalization. The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months
| Intervention | Percentage of participants with an event (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 90 days | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months | 42 months | |
| Anatomic Diagnostic Test | 1.0 | 1.2 | 1.8 | 2.5 | 2.9 | 3.5 | 4.6 | 5.3 |
| Functional Diagnostic Tests | 1.1 | 1.4 | 1.9 | 2.6 | 2.8 | 3.5 | 3.8 | 5.1 |
Forearm blood flow was measured by strain gauge plethysmography (NCT00685945)
Timeframe: During and after each study drug administration
| Intervention | ml/min/100ml (Mean) | |||
|---|---|---|---|---|
| FBF (bradykinin 0 ng/min) | FBF (bradykinin 50ng/min) | FBF (bradykinin 100ng/min) | FBF (bradykinin 200 ng/min) | |
| Control | 4.03 | 7.02 | 13.17 | 17.74 |
| Isosorbide + L-NMMA + Control | 2.18 | 4.73 | 6.83 | 9.91 |
| L-NMMA + Control | 2.36 | 5.16 | 8.67 | 11.21 |
| Sildenafil + L-NMMA + Control | 2.80 | 5.87 | 9.13 | 12.92 |
Individual net reuptake rates at each time point were calculated by the following formula: net uptake = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of glucose in the brachial vein and artery, respectively. (NCT00685945)
Timeframe: At baseline and after maximum dose of bradykinin
| Intervention | microgram/min/100ml (Mean) | |
|---|---|---|
| Net glucose uptake (bradykinin 0 ng/min) | Net glucose uptake (bradykinin 200 ng/min) | |
| Control | -79.95 | -319.85 |
| Isosorbide + L-NMMA + Control | -71.4 | -163.233 |
| L-NMMA + Control | -74.36 | -142.86 |
| Sildenafil + L-NMMA + Control | -67.3 | -125.32 |
Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively. (NCT00685945)
Timeframe: During and after each study drug administration
| Intervention | ng/min/100ml (Mean) | |||
|---|---|---|---|---|
| Net t-PA release (bradykinin 0ng/min) | Net t-PA release (bradykinin 50ng/min) | Net t-PA release (bradykinin 100ng/min) | Net t-PA release (bradykinin 200ng/min) | |
| Control | 0.24 | 1.02 | 11.81 | 30.03 |
| Isosorbide + L-NMMA + Control | -0.38 | 3.14 | 15.90 | 45.32 |
| L-NMMA + Control | 0.59 | 3.65 | 22.10 | 39.90 |
| Sildenafil + L-NMMA + Control | 0.29 | 2.46 | 18.48 | 37.39 |
37 reviews available for aspirin and Obesity
| Article | Year |
|---|---|
Preeclampsia in 2023: Time for preventing early onset- and term preeclampsia: The paramount role of gestational weight gain.
Topics: Aspirin; Body Mass Index; Female; Gestational Weight Gain; Humans; Infant, Newborn; Obesity; Pre-Ecl | 2023 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III.
Topics: Adult; Aspirin; Cardiovascular Diseases; Child; Diet; Dietary Supplements; Humans; Hydroxymethylglut | 2020 |
Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.
Topics: Alcohol Drinking; Aspirin; Carcinoma, Hepatocellular; Chronic Disease; Diabetes Mellitus, Type 2; Di | 2020 |
Obesity and Altered Aspirin Pharmacology.
Topics: Aspirin; Blood Platelets; Humans; Obesity; Platelet Aggregation Inhibitors | 2018 |
Influence of Smoking, Body Mass Index, and Other Factors on the Preventive Effect of Nonsteroidal Anti-Inflammatory Drugs on Colorectal Cancer Risk.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Colorectal Neoplasms; Diet; | 2018 |
Heterogeneity and the origins of asthma.
Topics: Animals; Aspirin; Asthma; Cigarette Smoking; Humans; Hypersensitivity, Immediate; Microbiota; Neutro | 2018 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part I.
Topics: Aspirin; Cardiovascular Diseases; Diet; Dietary Supplements; Humans; Hydroxymethylglutaryl-CoA Reduc | 2018 |
[Prevention of atherosclerosis in children--the role of statins and aspirin].
Topics: Adult; Aspirin; Atherosclerosis; Child; Comorbidity; Diabetes Mellitus; Dyslipidemias; Humans; Hydro | 2013 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; | 2014 |
Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Air Pollution; American Heart Association; | 2014 |
Type 2 diabetes and cardiovascular disease: what next?
Topics: Anticholesteremic Agents; Aspirin; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 2014 |
Preventing deaths due to the hypertensive disorders of pregnancy.
Topics: Aspirin; Birth Intervals; Calcium; Cardiotocography; Dietary Supplements; Eclampsia; Female; Food Su | 2016 |
Prediction and prevention of recurrent preeclampsia.
Topics: Adult; Antihypertensive Agents; Aspirin; Calcium, Dietary; Female; Fetal Growth Retardation; Heparin | 2008 |
Psoriasis: an opportunity to identify cardiovascular risk.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; F | 2009 |
Platelet activation in obesity and metabolic syndrome.
Topics: Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Metabolic Syndrome; Obesity | 2012 |
Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Case-Control Studies; Co | 2013 |
Environmental contributions to the allergic asthma epidemic.
Topics: Air Pollutants; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Child; Disease Outbreaks; | 2002 |
Prevention and treatment of diabetic nephropathy in older patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Aspirin; Blood Glucose; Clinical Trials as Topic; Diabet | 2003 |
Modifiable risk factors for the primary prevention of heart disease in women.
Topics: Activities of Daily Living; Anger; Antioxidants; Anxiety; Aspirin; Attitude to Health; Coronary Dise | 2003 |
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool.
Topics: Adult; Aged; Aspirin; Blood Coagulation Factors; Blood Group Antigens; Ethnicity; Gonadal Steroid Ho | 2003 |
Epidemiology of pancreatic cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cholecystectomy; Cholelithiasis; Chronic Disease; | 2004 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arte | 2004 |
[Primary prevention of cardiovascular disease].
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Aspirin; Body Mass Index; Cardiovascular Diseases | 2005 |
Metabolic syndrome.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Humans; Hydroxymethylglutaryl | 2006 |
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Ac | 2006 |
Stroke prevention in diabetes and obesity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular | 2006 |
[Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Dyslipidemias; Humans; Hy | 2006 |
[Cancer of the pancreas. Epidemiology and risk factors].
Topics: Adenomatous Polyposis Coli; Age Factors; Aged; Aspirin; Breast Neoplasms; Diabetes Mellitus, Type 2; | 2007 |
Primary prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Contraceptives, Oral; Diabetes Complications; Diet; Estrogen Rep | 1995 |
[Intervention in risk factors and protection of target organs].
Topics: Alcohol Drinking; Aspirin; Cerebrovascular Disorders; Diabetes Complications; Diabetes Mellitus; Est | 1997 |
[Late pregnancy toxicosis developing against a background of extragenital pathology and its prevention (a review)].
Topics: Adult; Aspirin; Female; Humans; Hypertension; Obesity; Pre-Eclampsia; Pregnancy; Risk Factors; Weigh | 1997 |
Risk factors for coronary heart disease in women.
Topics: Aged; Antioxidants; Aspirin; Cholesterol; Contraceptives, Oral; Coronary Disease; Diabetes Mellitus; | 1998 |
Dietary fat intake, supplements, and weight loss.
Topics: Animals; Anti-Obesity Agents; Aspirin; Carnitine; Citrates; Dietary Fats; Dietary Supplements; Ephed | 2000 |
Risk factors and primary prevention of ischemic heart disease in women.
Topics: Alcohol Drinking; Antioxidants; Aspirin; Diabetes Complications; Exercise; Female; Humans; Hyperlipi | 2001 |
C-reactive protein and cardiovascular disease: a review of risk prediction and interventions.
Topics: Age Factors; Arteriosclerosis; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Fe | 2002 |
Gold thioglucose obesity syndrome.
Topics: Adrenalectomy; Animals; Appetite Regulation; Aspirin; Aurothioglucose; Biological Transport; Capilla | 1977 |
The primary prevention of myocardial infarction.
Topics: Alcohol Drinking; Aspirin; Blood Glucose; Cholesterol; Estrogen Replacement Therapy; Female; Humans; | 1992 |
20 trials available for aspirin and Obesity
| Article | Year |
|---|---|
Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents - Results From the HOST-EXAM Trial.
Topics: Aspirin; Body Mass Index; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Obesit | 2023 |
Prospective, randomized, controlled, trial to assess ASA DOSing by body mass index in HEalthy volunteers (DOSE study).
Topics: Adult; Aspirin; Body Mass Index; Cardiovascular Diseases; Female; Healthy Volunteers; Humans; Male; | 2023 |
Persisting risk factors for preeclampsia among high-risk pregnancies already using prophylactic aspirin: a multi-country retrospective investigation.
Topics: Aspirin; Female; Folic Acid; Humans; Hypertension; Infant, Newborn; Obesity; Pre-Eclampsia; Pregnanc | 2023 |
Analysis of Body Mass Index in Early and Middle Adulthood and Estimated Risk of Gastrointestinal Cancer.
Topics: Adult; Aspirin; Body Mass Index; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; M | 2023 |
Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack.
Topics: Aspirin; Body Mass Index; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attac | 2023 |
Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; C-Reactive Protein; Chi-Square Distribution; Cyclooxyge | 2014 |
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronar | 2014 |
Is low-dose aspirin therapy to prevent preeclampsia more efficacious in non-obese women or when initiated early in pregnancy?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Female; Gestational Age; H | 2015 |
Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.
Topics: Adaptor Proteins, Signal Transducing; Adiposity; Adult; Anti-Inflammatory Agents, Non-Steroidal; Asp | 2015 |
Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thromb | 2010 |
Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus.
Topics: Adult; Alanine Transaminase; Aspirin; Blood Glucose; Body Mass Index; Cholesterol, LDL; Confidence I | 2010 |
The fat-mass and obesity-associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women.
Topics: Alleles; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Aspirin; Body Mass Index; Cardiovascular Dis | 2010 |
Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cohort Studies; Co | 2012 |
Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; H | 2013 |
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Topics: Aged; Aspirin; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; | 2003 |
Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
Topics: Abortion, Induced; Abortion, Spontaneous; Aspirin; Blood Pressure; Female; Humans; Logistic Models; | 1995 |
Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity.
Topics: Adult; Aspirin; Caffeine; Drug Therapy, Combination; Energy Intake; Ephedrine; Female; Humans; Male; | 1993 |
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Topics: Acute Disease; Age Factors; Aged; Angina, Unstable; Aspirin; Brain Damage, Chronic; Cerebral Hemorrh | 1999 |
Roles of deoxycholate and arachidonate in pathogenesis of cholesterol gallstones in obese patients during rapid loss of weight.
Topics: Arachidonic Acid; Arachidonic Acids; Aspirin; Cholelithiasis; Cholesterol; Deoxycholic Acid; Dinopro | 1991 |
Ephedrine, caffeine and aspirin promote weight loss in obese subjects.
Topics: Adult; Aspirin; Caffeine; Drug Therapy, Combination; Ephedrine; Female; Humans; Male; Obesity; Weigh | 1990 |
104 other studies available for aspirin and Obesity
| Article | Year |
|---|---|
Aspirin Use for Preeclampsia Prevention Among Women With Prepregnancy Diabetes, Obesity, and Hypertension.
Topics: Adolescent; Adult; Aspirin; Female; Humans; Hypertension; Length of Stay; Obesity; Pre-Eclampsia; Pr | 2022 |
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Humans; Obesity; Overweight | 2023 |
Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study.
Topics: Aspirin; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; | 2022 |
Risk factors for small-intestinal mucosal breaks beyond aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Capsule Endoscopy; Humans; Intestinal Mucosa; Obes | 2022 |
Aspirin attenuates the expression of adhesion molecules, risk of obesity, and adipose tissue inflammation in high-fat diet-induced obese mice.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents; Aspirin; Blood Glucose; Body Weight; Diet, High-F | 2022 |
Physiologically based modelling of the antiplatelet effect of aspirin: A tool to characterize drug responsiveness and inform precision dosing.
Topics: Aspirin; Blood Platelets; Humans; Models, Theoretical; Obesity; Platelet Aggregation Inhibitors; Thr | 2022 |
Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer.
Topics: Aged; Aspirin; Body Mass Index; Colorectal Neoplasms; Cross-Sectional Studies; Female; Humans; Male; | 2022 |
Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Topics: Aged; Aspirin; Body Mass Index; Clinical Trials as Topic; Cohort Studies; Colorectal Neoplasms; Fema | 2019 |
Response by Chen et al to Letter Regarding Article, "Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity".
Topics: Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Obesity; Overweight; Stroke | 2020 |
Letter by L. Schlemm and E. Schlemm Regarding Article, "Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity".
Topics: Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Obesity; Overweight; Stroke | 2020 |
Aspirin Modifies Inflammatory Mediators and Metabolomic Profiles and Contributes to the Suppression of Obesity-Associated Breast Cancer Cell Growth.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Aspirin; Breast; Breast Neoplasms; Cell Different | 2020 |
Associations between daily aspirin use and cancer risk across strata of major cancer risk factors in two large U.S. cohorts.
Topics: Aged; Aspirin; Body Mass Index; Diet; Early Detection of Cancer; Female; Humans; Male; Middle Aged; | 2021 |
Effect of acetylsalicylic acid on inflamed adipose tissue. Insulin resistance and hepatic steatosis in a mouse model of diet-induced obesity.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diet, High-Fat; Disease M | 2021 |
Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity.
Topics: Aged; Angioplasty; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Dual Anti-Platelet | 2021 |
Risk factors among stroke subtypes and its impact on the clinical outcome of patients of Northern Portugal under previous aspirin therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cohort Studies; Dyslipidemias; F | 2021 |
Sex Differences in Coronary Arterial Calcification in Symptomatic Patients.
Topics: Adult; Aspirin; Chest Pain; Cohort Studies; Computed Tomography Angiography; Coronary Angiography; C | 2021 |
Aspirin Resistance in Obese and Elderly Patients with COVID-19?
Topics: Aged; Aspirin; COVID-19; Humans; Obesity; Outpatients; SARS-CoV-2 | 2021 |
Pre-diagnostic aspirin use and mortality after breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; | 2018 |
Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; Diet, High-Fat; Female; Gluc | 2019 |
Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2019 |
BMS consensus statement for primary prevention of coronary heart disease in women.
Topics: Age Factors; Antihypertensive Agents; Aspirin; Coronary Disease; Diet; Estrogen Replacement Therapy; | 2019 |
Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin Receptor Antagonists; Aspirin; Card | 2013 |
Polymorphisms and high on-aspirin platelet reactivity after off-pump coronary artery bypass grafting.
Topics: Aged; Analysis of Variance; Asian People; Aspirin; Case-Control Studies; Chi-Square Distribution; Ch | 2013 |
Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study.
Topics: Adult; Aspirin; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Complicat | 2013 |
Acute respiratory distress syndrome after spontaneous intracerebral hemorrhage*.
Topics: Acute Lung Injury; Aged; Aspirin; Cerebral Hemorrhage; Cohort Studies; Erythrocyte Transfusion; Fema | 2013 |
Aspirin and low-molecular weight heparin combination therapy effectively prevents recurrent miscarriage in hyperhomocysteinemic women.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Heparin, Low- | 2013 |
Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes.
Topics: Asian People; Aspirin; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Resista | 2014 |
Age-related prevalence of diabetes mellitus, cardiovascular disease and anticoagulation therapy use in a urolithiasis population and their effect on outcomes: the Clinical Research Office of the Endourological Society Ureteroscopy Global Study.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiovascula | 2015 |
Long-term survival following bariatric surgery in the VA health system.
Topics: Aspirin; Bariatric Surgery; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Ob | 2015 |
Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
Topics: Activation, Metabolic; Aged; Aspirin; Brachial Artery; Clopidogrel; Coronary Disease; Cytochrome P-4 | 2015 |
Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention.
Topics: Aged; Angina, Stable; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Obesity; Percutaneous | 2015 |
Isolated brachiocephalic artery dissection presenting as acute stroke.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Aortic Dissection; Aspirin; Ataxia; Brachiocephalic | 2015 |
Management of acute coronary syndromes in a developing country; time for a paradigm shift? an observational study.
Topics: Acute Coronary Syndrome; Aged; Alcoholism; Angina, Unstable; Aspirin; Delayed Diagnosis; Developing | 2015 |
Medical research: Time to think differently about diabetes.
Topics: Adipose Tissue; Animals; Aspirin; Bariatric Surgery; Bile Acids and Salts; Biomedical Research; Bloo | 2016 |
Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Comorbidity; Diabetes Mellit | 2016 |
Aspirin prevents bone loss with little mechanical improvement in high-fat-fed ovariectomized rats.
Topics: Animals; Aspirin; Biomarkers; Biomechanical Phenomena; Body Weight; Bone Density; Diet, High-Fat; Fe | 2016 |
Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
Type 2 Diabetes, Obesity, and Aspirin Responsiveness.
Topics: Aspirin; Diabetes Mellitus, Type 2; Humans; Obesity; Platelet Aggregation Inhibitors; Thromboxane B2 | 2017 |
Stemming the obesity-diabetes epidemic: lifestyle changes and therapeutics.
Topics: Aspirin; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hy | 2008 |
Obesity in aspirin-tolerant and aspirin-intolerant asthmatics.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Aspirin; Asthma; Body Mass Index; Bron | 2008 |
Low-dose acetylsalicylic acid inhibits the secretion of interleukin-6 from white adipose tissue.
Topics: Adipocytes; Adipose Tissue, White; Aged; Animals; Aspirin; Case-Control Studies; Cyclooxygenase Inhi | 2008 |
The effect of anti-inflammatory (aspirin and/or statin) therapy on body weight in Type 2 diabetic individuals: EAT, a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, | 2009 |
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coro | 2009 |
Aspirin attenuates insulin resistance in muscle of diet-induced obese rats by inhibiting inducible nitric oxide synthase production and S-nitrosylation of IRbeta/IRS-1 and Akt.
Topics: Animals; Aspirin; Drug Tolerance; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; | 2009 |
Endogenous nitric oxide contributes to bradykinin-stimulated glucose uptake but attenuates vascular tissue-type plasminogen activator release.
Topics: Adult; Aspirin; Bradykinin; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibito | 2010 |
Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Case-Control Studies; Drug | 2009 |
Effect of obesity on platelet reactivity and response to low-dose aspirin.
Topics: Adult; Arachidonic Acid; Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Co | 2010 |
USPSTF recommendations you may have missed amid the breast cancer controversy.
Topics: Adolescent; Age Factors; Aspirin; Breast Neoplasms; Breast Self-Examination; Child; Depression; Depr | 2010 |
Long-term anticoagulation with fondaparinux in a patient with a mechanical heart valve.
Topics: Anticoagulants; Aortic Valve Stenosis; Aspirin; Drug Therapy, Combination; Fondaparinux; Heart Valve | 2011 |
Treatment of GERD and proton pump inhibitor use in the elderly: practical approaches and frequently asked questions.
Topics: Adenocarcinoma; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; Barrett Esop | 2011 |
Differences in the mode of presentation for acute coronary syndrome by pre-hospitalization medication, in relation to coronary risk factors, East-Osaka acute coronary syndrome (EACS) registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Coronary Arte | 2011 |
Obesity and aspirin intolerance are risk factors for difficult-to-treat asthma in Japanese non-atopic women.
Topics: Adult; Aged; Asian People; Aspirin; Asthma; Body Mass Index; Drug Hypersensitivity; Female; Humans; | 2012 |
Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era.
Topics: Adult; Aged; Aspirin; Body Mass Index; Cohort Studies; Female; Heart Transplantation; Heart-Assist D | 2012 |
Obesity: is it a major risk for developing aspirin resistance in older adults?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Resistance; Egypt; Female; Geriatric As | 2012 |
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combi | 2012 |
Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplas | 2012 |
An aspirin a day: the allure (and distraction) of chemoprevention.
Topics: Alcohol Drinking; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin | 2012 |
[The risk factors for colonic diverticular bleeding].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calci | 2012 |
Body mass index predicts failure of surgical management in benign prostatic hyperplasia.
Topics: Aged; Aspirin; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; | 2013 |
Comparison of secondary prevention of heart disease in Europe: lifestyle getting worse, therapy getting better in Ireland.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Mellitus, T | 2002 |
Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study.
Topics: Aged; Anticholesteremic Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol; Engla | 2003 |
Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects.
Topics: Adenosine Diphosphate; Analysis of Variance; Arachidonic Acid; Arteriosclerosis; Aspirin; Blood Gluc | 2003 |
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hyper | 2003 |
LONG-TERM TREATMENT OF A PATIENT WITH RHEUMATOID ARTHRITIS.
Topics: Arthritis, Rheumatoid; Aspirin; Braces; Casts, Surgical; Contracture; Diabetes Mellitus; Drug Therap | 1964 |
Hypertension and insulin resistance are not directly related in obese dogs.
Topics: Adrenergic beta-Antagonists; Animals; Aspirin; Atenolol; Blood Glucose; Clonidine; Diet, Sodium-Rest | 2004 |
Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999.
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Agents; China; Coronary Disease; Devel | 2004 |
Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?
Topics: Adult; Aged; Alleles; Aspirin; Drug Resistance; Dyslipidemias; Female; Gene Frequency; Genotype; Hum | 2005 |
[Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida].
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Clopidogrel; Humans; Hypercholesterolemia; Obesi | 2005 |
Association between body mass index and CKD in apparently healthy men.
Topics: Adult; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Chronic Disease; Cohort Stu | 2005 |
Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Brain; Dementia, Va | 2005 |
[Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France].
Topics: Adolescent; Adult; Aged; Aspirin; Biguanides; Cerebrovascular Disorders; Coronary Disease; Cost-Bene | 2005 |
The metabolic syndrome--what is it and how should it be managed?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA | 2006 |
Evaluating and treating cardiometabolic risk factors: a case discussion.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diet; Dyslipidemias; Exercise; Female; Heart Dise | 2006 |
Inhibitory effects of cardiotonic pills on platelet function in dogs fed a high-fat diet.
Topics: Animals; Aspirin; Blood Platelets; Calcium; Cardiotonic Agents; Dietary Fats; Disease Models, Animal | 2006 |
The rate of checking urine microalbumin and aspirin primary prevention in type 2 DM.
Topics: Albuminuria; Aspirin; Atherosclerosis; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hyp | 2006 |
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplasms; Databases | 2007 |
Clinical decisions. Management of stable coronary disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coronary Disease; Diabetes Me | 2007 |
[Family practice highlights of stomach, liver and intestinal reference points. Your arsenal against abdominal problems].
Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Family Practi | 2007 |
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastati | 2008 |
Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database.
Topics: Acute Coronary Syndrome; Adult; Age Distribution; Aged; Aged, 80 and over; Angina, Unstable; Aspirin | 2008 |
Secondary prevention of coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Diabetes Mellitus; Feeding B | 1984 |
Postoperative venous thrombosis. Evaluation of five methods of treatment.
Topics: Adult; Age Factors; Aged; Aspirin; Clothing; Dextrans; Female; Fibrinogen; Heparin; Humans; Iodine R | 1981 |
Indomethacin and aspirin prevent the starvation-induced fall in plasma insulin.
Topics: Adult; Aspirin; Female; Glucagon; Humans; Indomethacin; Insulin; Kinetics; Male; Middle Aged; Obesit | 1980 |
Epidemiological feasibility of cardiovascular primary prevention in general practice: a trial of vitamin E and aspirin. Collaborative group of the Primary Prevention Project.
Topics: Aged; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clinical Protocols; Contraindications; Dia | 1995 |
Ephedrine, Xanthines, Aspirin and Other Thermogenic Drugs to Assist the Dietary Management of Obesity. Proceedings of an international symposium. Geneva, 24-26 September 1992.
Topics: Animals; Aspirin; Ephedrine; Humans; Obesity; Xanthines | 1993 |
Effects of weight loss, ephedrine and aspirin on energy expenditure in obese women.
Topics: Adult; Aspirin; Basal Metabolism; Energy Metabolism; Ephedrine; Exercise; Female; Humans; Obesity; R | 1993 |
Post-prandial thermogenesis with ephedrine, caffeine and aspirin in lean, pre-disposed obese and obese women.
Topics: Adult; Aspirin; Basal Metabolism; Body Constitution; Body Mass Index; Body Temperature Regulation; C | 1996 |
A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Cardiac Care Facilities; Cardiology; Cholesterol; | 1996 |
Secular trends in stroke mortality in African Americans: the role of urbanization, diabetes and obesity.
Topics: Adult; Aged; Aspirin; Black People; Cerebrovascular Disorders; Diabetes Mellitus; Female; Fibrinolyt | 1997 |
Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Aspirin; Co | 1998 |
Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey.
Topics: Adult; Albuminuria; Angina Pectoris; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabe | 2001 |
ABCs of secondary prevention of CHD: easier said than done.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Aspirin; Coronary Disease; Diet; Exercise; Hu | 2001 |
Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Glucose; Cell Line; Dietary Fats; G | 2001 |
[Arterial hypertension - the specific case].
Topics: Aspirin; Carotid Artery, Internal; Carotid Stenosis; Diabetes Complications; Diet; Exercise; Follow- | 2001 |
Prostaglandins and obesity.
Topics: Adipose Tissue; Aspirin; Humans; Obesity; Prostaglandin Antagonists; Prostaglandins E; Prostaglandin | 1978 |
[Problems of arteriosclerosis epidemiology. Analysis of risk factors with a view to a possible therapy].
Topics: Anti-Inflammatory Agents; Anticoagulants; Antihypertensive Agents; Arteriosclerosis; Aspirin; Blood | 1976 |
Renal excretion of uric acid during prolonged fasting.
Topics: Adolescent; Adult; Aspirin; Bicarbonates; Fasting; Female; Humans; Hydroxybutyrates; Kidney; Lactate | 1976 |
Aspirin potentiates the effect of ephedrine on the thermogenic response to a meal in obese but not lean women.
Topics: Adult; Analysis of Variance; Anthropometry; Aspirin; Basal Metabolism; Body Temperature Regulation; | 1991 |
Prevention of cardiovascular disease. Of what value are risk factor modification, exercise, fish consumption, and aspirin therapy?
Topics: Animals; Aspirin; Cardiovascular Diseases; Feeding Behavior; Fish Products; Humans; Hyperlipidemias; | 1987 |
Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aspirin; Body Weight; Female; Humans; Infusions, Par | 1986 |
Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity.
Topics: Adipose Tissue; Animals; Aspirin; Body Temperature Regulation; Drug Therapy, Combination; Energy Met | 1987 |
Femoral artery laceration complicating an intertrochanteric hip fracture: a multi-disciplinary therapeutic problem.
Topics: Aged; Aspirin; Embolization, Therapeutic; Female; Femoral Artery; Hematoma; Hip Fractures; Humans; O | 1985 |
The effect of variation of lipolysis after nicotinic acid and acetylsalicylate on blood concentrations of 3-hydroxybutyrate and acetoacetate in starving subjects.
Topics: Acetoacetates; Adolescent; Adult; Aspirin; Blood Glucose; Diabetes Mellitus; Fatty Acids, Nonesterif | 1970 |
Polyarthritis in obese patients with intestinal bypass.
Topics: Adolescent; Adult; Arthritis; Aspirin; Body Height; Body Weight; Colon; Dehydration; Female; Humans; | 1971 |